Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.47 |
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | HTR2B | P41595 | 8/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21003264 | 0.88 | HTR2C (0.40) | HTR2CHTR2AHTR2BCHRM3PDE10A | |
| SCHEMBL26866100 | 0.78 | HTR2C (0.43) | HTR2CHTR2AHTR2BCHRM3CHRM2 | |
| SCHEMBL21035800 | 0.74 | HTR2C (0.45) | HTR2CHTR2AHTR2BCHRM3CHRM2 | |
| SCHEMBL24730855 | 0.74 | HTR2C (0.41) | HTR2CCHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL3421865 | 0.73 | HTR2A (0.45) | HTR2CHTR2AHTR2BPDE10A | |
| SCHEMBL4393506 | 0.73 | HTR2C (0.40) | HTR2CHTR2AHTR2BCHRM3CHRM2 | |
| SCHEMBL14483531 | 0.73 | HTR2C (0.34) | HTR2CHTR2AHTR2BCHRM3 | |
| Hydrochloric Acid SCHEMBL1262001 | 0.72 | HTR2A (0.44) | HTR2CHTR2AHTR2BPDE10A | |
| SCHEMBL16210048 | 0.70 | HTR2C (0.51) | HTR2CHTR2AHTR2BCHRM3PDE10A | |
| SCHEMBL30793125 | 0.70 | HTR2C (0.50) | HTR2CHTR2AHTR2BCHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3717488-B1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | HTR2C 2093/4885HTR2A 1202/4885HTR2B 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.